BIM 21009

• UNSPSC Description:

  BIM 21009 is a LHRH and GnRH receptor antagonist. BIM 21009 inhibits tumor growth[1].

• Target Antigen:

  GnRH Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bim-21009.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CC2=CC=CC=C2)NC([C@@H](CCCNC(N)=N)NC([C@H](CC3=CC=C(O)C=C3)NC([C@H](CO)NC([C@@H](CC4=CC=CC=C4)NC([C@@H](CC5=CC=C(Cl)C=C5)NC([C@@H](CC6=CC=C7C=CC=CC7=C6)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O

• Molecular Weight:

  1463.08

• References & Citations:

  [1]Ban E, Crumeyrolle-Arias M, Latouche J, Leblanc P, Heurtier JF, Drieu K, Fillion G, Haour F. GnRH receptors in rat brain, pituitary and testis; modulation following surgical and gonadotropin-releasing hormone agonist-induced castration. Mol Cell Endocrinol. 1990 Mar 26;70(1):99-107.|[2]Bogden AE,et al. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res. 1990 May 1;50(9):2646-50.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  106881-54-3